CDK4/6 inhibitor palbociclib promotes SARS-CoV-2 cell entry by down-regulating SKP2 dependent ACE2 degradation

Coronavirus disease 2019 (COVID-19) outbreak has become a global pandemic. CDK4/6 inhibitor palbociclib was reported to be one of the top-scored repurposed drugs to treat COVID-19. As the receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry, expression level of angiotensin...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Yingzi, Yan, Ying, Chang, Le, Ji, Huimin, Sun, Huizhen, Song, Shi, Feng, Kaihao, Nuermaimaiti, Abudulimutailipu, Lu, Zhuoqun, Wang, Lunan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938000/
https://www.ncbi.nlm.nih.gov/pubmed/36806814
http://dx.doi.org/10.1016/j.antiviral.2023.105558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938000/
https://www.ncbi.nlm.nih.gov/pubmed/36806814
http://dx.doi.org/10.1016/j.antiviral.2023.105558

Ejemplares similares